Details

Autor(en) / Beteiligte

• Montastruc, François
• Salvo, Francesco
• Arnaud, Mickaël
• Bégaud, Bernard
• Pariente, Antoine

Titel

Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase

Ist Teil von

• Drug safety, 2016-07, Vol.39 (7), p.689-696

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2016

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Introduction Investigations have highlighted the lack of evidence regarding the likelihood of congenital malformations following exposure to antipsychotic drugs during pregnancy. To gain further knowledge regarding their safety, we evaluated signals of congenital malformations with antipsychotics using VigiBase ® , the World Health Organization (WHO) Global Individual Case Safety Report (ICSR) database. Method A case/non-case study was conducted in VigiBase ® between 1967 and 2014. Signals of disproportionate reporting (SDRs) were detected using the proportional reporting ratio (PRR), which defines SDRs as drug-report associations with a PRR ≥2, Chi square ≥4, and number of cases ≥3. SDR detection for antipsychotics was performed for congenital malformations after removing all reports related to drug competitors and reports of movement disorders from the database. Results After removing reports related to drug competitors (antiepileptics, antidepressants, antivirals) and movement disorders, three signals were revealed: ‘palate disorders congenital’ (PRR 2.1, 95 % CI 1.6–2.9, Chi square = 30; n  = 41), ‘oesophageal disorders congenital’ (PRR 2.5, 95 % CI 1.3–4.7, Chi square = 11; n  = 10) and ‘anorectal disorders congenital’ (PRR 3.0, 95 % CI 1.6–5.6, Chi square = 13; n  = 11). Among antipsychotics, phenothiazines with a piperazine side-chain, risperidone and aripiprazole appeared to be more suspect. Conclusion Confirming a first signal from spontaneous reporting data, three SDRs for antipsychotics and gastrointestinal congenital abnormalities were unmasked in VigiBase ® . This signal should be further explored by ad hoc pharmacoepidemiologic studies in order to assess whether it is relevant for prescription and public health.